Short term adverse event profile of COVID-19 mRNA vaccines in children aged 5–15 years in Australia

Australia commenced its COVID-19 vaccine program for children aged 12–15 years from
July 2021 and for children aged 5–11 years from January 2022 with two primary doses
of either Comirnaty (Pfizer–BioNTech BNT162b2, 10 μg for 5–11 years and 30 μg for
12–15 years) or Spikevax (Moderna mRNA-1273, 50 μg for 6–11 years and 100 μg for 12–15
years), 8 weeks apart. A booster dose is recommended for those aged 5–15 years with
complex health conditions or severe immunocompromise.

Related Keywords

Australia , United States , Sydney , New South Wales , Australian , Spikevax Moderna , Australian Department Of Health , Rr Development Core Team , Sydney Children Hospitals Network , Wa Vaccine Safety Advisory Committee , R Foundation For Statistical Computing , Statistical Computing , Sydney Children , Hospitals Network , Supplementary Table , Torres Strait , Englj Med , Safety Advisory , Professor Macartney , Australian Department ,